[{"id":"6f7d4152-8883-4202-b09b-1e6eca244083","acronym":"","url":"https://clinicaltrials.gov/study/NCT05233618","created_at":"2023-08-14T10:11:07.430Z","updated_at":"2025-02-25T17:01:40.560Z","phase":"Phase 1","brief_title":"Study of Tagraxofusp for Post-Transplant Maintenance for Patients with CD 123+ AML, MF and CMML (HSCT 002)","source_id_and_acronym":"NCT05233618","lead_sponsor":"Karen Ballen, MD","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elzonris (tagraxofusp-erzs) • SL-701"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-03"}]